Skip to main content
. 2021 Aug 7;9(8):976. doi: 10.3390/biomedicines9080976

Figure 7.

Figure 7

The combination of hydralazine and enzalutamide decreased cell proliferation in PCa (prostate cancer) cells. Percentage of cell proliferation (evaluated by BrdU assay). Values were normalized to the vehicle condition (A). Corresponding cell cycle analysis of PCa cells (B). (V—vehicle, H—hydralazine, E—enzalutamide, H+E—combination of hydralazine and enzalutamide).